C

Cleerly

AI-driven cardiovascular imaging analytics platform

Regional Sales Manager - Provider Sales

Full-TimeUpdated on 10/21/2026
$140k - $150k+ $150,000 Commission
Mid, Senior
Bachelor's
Minneapolis, MN, USA
HybridMust be located in or near Minneapolis and able to travel overnight 75% of the time.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree or equivalent work experience is required.
  • Successful sales experience in a startup organization is required.
  • Five to eight years of customer-facing sales experience in medical device sales, medtech sales, account relationship management, or client services is required, including at least three years in a closing role.
  • Experience managing high-value accounts through high-touch customer partnerships is required.
  • Experience working in technology environments and familiarity with technical concepts are required.
  • A track record of strong customer service and the ability to convey complex concepts to people with less technical experience are required, as are the abilities to negotiate, establish consensus, and gain agreement.
  • The ability to solve customer needs involving technical products with innovative and creative approaches is required.
  • The ability to work independently and as part of a virtually collaborative team is required.
  • The ability to work cross-functionally across multiple geographies and time zones each day is required.
  • The ability to adapt information and communication style to the audience and explain difficult concepts concisely is required.
  • Experience managing ambiguity is required.
  • The ability to travel overnight 75% of the time is required.
Responsibilities
  • Actively manage a high-value portfolio within the defined sales territory of Minnesota, North Dakota, South Dakota, Iowa, and Wisconsin.
  • Prospect and develop new business to drive revenue by identifying cross-selling and expansion opportunities across commercial models and Cleerly's business offerings.
  • Deliver weekly, monthly, and quarterly reports on the sales pipeline, revenue, and other important data.
  • Develop and deliver proposals, position complex pricing structures, and negotiate contracts and deal-closing requirements.
  • Execute sales strategies to increase utilization of the Cleerly solution across assigned geographies and diverse customers, collaborating with the strategy and customer success teams to convert accounts.
  • Meet quarterly and annual sales goals by developing account strategies and pipelines, maintaining sales reports, and developing market and competitor knowledge.
  • Give presentations and training, and travel to customer sites as needed.
  • Represent Cleerly at industry conferences and maximize opportunities by targeting specific leads.
Desired Qualifications
  • Previous experience in digital health and SaaS or software as a medical device (SaMD) sales is preferred.
  • Experience using customer relationship management (CRM) systems and advanced data analytics tools is preferred.

About the company

C

Cleerly

View
cbWebsite

Cleerly Health provides an AI-powered digital platform for cardiovascular care. It analyzes coronary CT angiography (CCTA) heart scans to identify and measure atherosclerosis, including different plaque types, helping clinicians assess heart attack risk more accurately. The platform converts complex imaging data into actionable insights, enabling personalized treatment plans for patients and improved clinical and financial outcomes for healthcare providers. Unlike traditional methods that rely on general risk factors, Cleerly focuses on precise plaque characterization and integrates imaging analysis with care management tools. The company’s goal is to help clinicians diagnose and treat heart disease more precisely, improving patient health while delivering better outcomes for providers.

Company Size

201-500

Company Stage

Series C

Total Funding

$417.8M

Headquarters

Denver, Colorado

Founded

2017

Get referred to Cleerly

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • MemorialCare launched Cleerly systemwide in May 2026 across three Southern California hospitals.
  • Medicare and major insurers now cover AI plaque analysis for symptomatic patients.
  • SCCT2026 and ACC.26 presentations extended Cleerly's clinical credibility with new registry data.

What critics are saying

  • Heartflow sued Cleerly in April 2026, seeking damages and an injunction.
  • Cleerly's CLIA polygenic test carries ancestry-performance limits and no FDA clearance.
  • If Medicare coverage narrows, hospital adoption stalls and Cleerly's commercialization breaks.

What makes Cleerly unique

  • FDA-cleared AI-QCT quantifies coronary plaque beyond calcium scores.
  • Cleerly PREVIEW and Full Text Reports embed workflow support into hospital imaging.
  • Allelica partnership adds polygenic risk alongside CCTA plaque analysis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical, dental, and vision plans
  • Stock Options
  • 401(k) matching program
  • Company wide holidays
  • Self-managed PTO

Growth & Insights and Company News

Headcount

6 month growth

13%

1 year growth

14%

2 year growth

14%
Cleerly
Oct 8th, 2026
Cleerly's TRANSFORM Trial sends a mobile CT scanner across the south to reach patients in underserved communities.

Cleerly's TRANSFORM Trial sends a mobile CT scanner across the south to reach patients in underserved communities. Cleerly: October 8, 2026 Operated with Clear Heart and Lung, the unit enables patients in communities without cardiac CT to join TRANSFORM, a trial testing whether treatment guided by coronary artery disease staging prevents heart attacks DENVER, October 8, 2026 - Cleerly, a leader in advanced cardiovascular imaging analysis, and Clear Heart and Lung Imaging, a leader in outpatient imaging care, have taken a cardiac-capable mobile CT scanner across the southern United States to expand access to cardiovascular research and enable communities and clinics to participate in Cleerly's TRANSFORM Trial. From July through September 2026, the CT scanner traveled through Arizona, Louisiana, Georgia, and Florida, bringing cardiovascular imaging and clinical trial access to communities with limited access to cardiac imaging. The unit carries a dedicated cardiovascular CT machine that captures the heart in a single heartbeat at 140 mm coverage, producing high-quality images of the coronary arteries that permit accurate assessment of atherosclerotic burden. This enables staging of coronary artery disease (CAD) and treatment tailored to CAD Stage in those patients randomized to the interventional arm of TRANSFORM. "Patients in underserved communities can face barriers to participating in clinical trials, which can limit the generalizability of trial results," said Udo Hoffmann, MD, MPH, Chief Medical, Scientific, and AI Officer of Cleerly. "The mobile CT scanner allows us to bring coronary CTA to clinics and patients who may otherwise have limited access to advanced imaging. This supports Cleerly's mission to create a world without heart attacks everywhere through a diagnose, stage, and treat approach to CAD, and helps broaden the diversity and geographic representation of TRANSFORM participants." "Clear Heart and Lung Imaging was founded on the belief that access to advanced cardiovascular imaging remains a challenge in America," said Kim Mischo, founder of Clear Heart and Lung Imaging. "The Clear Heart Mobile helps expand access to cardiovascular imaging, particularly in underserved communities. We're honored to partner with the TRANSFORM trial team, and with CT Coachworks, who built us the perfect mobile solution. Together we're bringing advanced cardiac imaging directly to patients who may otherwise have limited access to care, and expanding who gets to take part in cardiovascular research." About the TRANSFORM trial TRANSFORM is the only randomized, event-driven outcomes trial evaluating an AI-guided approach to staging and treating coronary artery disease in patients at increased risk for heart attacks. The trial is testing whether diagnosis, staging, and treatment of CAD, guided by Cleerly's investigational Coronary Artery Disease Staging System, reduces heart attacks and other cardiovascular events more effectively than care based on traditional risk factors alone. Cleerly's AI-QCT technology quantifies and characterizes coronary plaque at sub-millimeter resolution, and based on the quantitative assessment of plaque, stenosis, and ischemia burden, assigns a proprietary four-tier CAD staging system, which is the basis for how intensively patients are treated. TRANSFORM is active at 125 sites across the US and aims to randomize participants who are eligible if they are men over 55 or women over 65 who have diabetes and are otherwise free of symptoms of cardiovascular disease. Primary results are anticipated in 2029. TRANSFORM is led by study chair Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI of the Mount Sinai Fuster Heart Hospital, and co-chair David J. Maron, MD of Stanford University School of Medicine, and coordinated by Marc P. Bonaca, MD, MPH, FACC, FAHA at CPC Clinical Research. To learn more about the TRANSFORM trial, visit TransformTrial.org. Full eligibility criteria and participating sites are listed at ClinicalTrials.gov under identifier NCT06112418. Learn more about Clear Heart and Lung Imaging's technology and mission at ClearHeartAndLung.com. About Cleerly Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerly.com.

Cleerly
Sep 17th, 2026
Newsroom: Cleerly Launches With $43MM Series B

From More than a Decade of Clinical Research, Company Unveils Non-Invasive Approach to Identify, and New Care Pathways to Address Heart Disease Using AI.

Cardiac Vascular News
Jul 30th, 2026
Cleerly and Allelica partner to launch a polygenic Risk Score Test for coronary artery disease.

Cleerly and Allelica partner to launch a polygenic Risk Score Test for coronary artery disease. More in coronary/structural heart: SAN FRANCISCO-(BUSINESS WIRE)- #AI-Cleerly, a leader in advanced cardiac imaging analysis, and Allelica, a precision medicine company specializing in multi-ancestry polygenic risk scores (PRS), today announced a partnership to launch the Cleerly Polygenic Cardiovascular Risk Score Test, powered by Allelica. The test gives physicians a new option to identify and evaluate individuals with an inherited predisposition to coronary plaque. The Cleerly Polygenic Cardiovascular Risk Score Test can be used See full post here as originally published on this site

HealthTech HotSpot
Jul 7th, 2026
Cleerly to debut customizable Full Text reports and present new AI-QCT research at SCCT2026.

Cleerly to debut customizable Full Text reports and present new AI-QCT research at SCCT2026. New Full Text Report Configurability and Six Scientific Presentations at the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography DENVER-(BUSINESS WIRE)-#AI - Cleerly, a leader in advanced cardiovascular imaging analysis, will be attending the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT2026). The conference will take place July 9-12, 2026, at the Gaylord Pacific Resort in Chula Vista, California. SCCT2026 brings together clinicians and researchers from around the world to advance the science and practice of cardiovascular computed tomography. Cleerly will debut new customization capabilities for its Full Text Report, giving provider teams the ability to configure the structured narrative generated by its artificial intelligence-enabled quantitative computed tomography (AI-QCT) platform to their preference. In addition, Cleerly will present findings from six scientific abstracts spanning plaque quantification, risk stratification, and cardiovascular outcomes, including five studies that draw on data from the CONFIRM2 Registry. CONFIRM2 is a multicenter, international, observational cohort targeting 30,000 patients, with more than 10,750 participants currently enrolled, that aims to perform comprehensive quantification of computed tomography (CT) angiography findings and relate them to clinical variables and cardiovascular outcomes. New Full Text Report Customization The Full Text Report is a structured narrative populated with Cleerly LABS plaque analysis and Cleerly ISCHEMIA and generated using a site-configurable report template. It provides a clinician-ready summary of the coronary computed tomography angiography (CCTA) analysis across five key domains: * Atherosclerosis: Plaque volumes, including total plaque volume (TPV), calcified plaque (CP), noncalcified plaque (NCP), and low-density noncalcified plaque (LD-NCP), with percent atheroma volume (PAV), reported at both the patient and territory levels. * Stenosis: Per-segment diameter stenosis grouped by category (Severe, Moderate, Mild, Minimal, and Zero), with segment counts and lists. * Ischemia and CAD-RADS: Cleerly ISCHEMIA status with implicated vessels, plus the overall Coronary Artery Disease Reporting and Data System (CAD-RADS) score. * Anatomy: Coronary dominance, stents, chronic total occlusions (CTOs), anomalies, bifurcated lesions, and exclusions with documented reasons. * Site-configurable report template: The Full Text Report can be generated using site-configurable report templates to support individual clinical workflows. Report templates allow customization of sections, field order, headings, and static text. Blank sections are omitted automatically, and clinically appropriate phrasing is generated based on the analysis findings. "The Full Text Report brings together all the information a clinician needs to understand a patient's full coronary profile, including plaque burden, stenosis severity, ischemia status, and anatomy. By making that output configurable to each practice's workflow, the depth of AI-QCT analysis can translate easily into clinical action. We look forward to connecting with the SCCT community. Stop by one of our sessions or come see us at Booth #301," said James K. Min, MD, founder and CEO of Cleerly. Conference Schedule Thursday, July 9 Friday, July 10 * 7:00-7:50 AM | Cleerly Breakfast Symposium: Plaque Evolution: How AI & Serial Scanning Can Change the Game | Chula Vista 6 * Speakers: * James K. Min, MD, Founder & CEO, Cleerly * Udo Hoffmann, MD, MPH, Chief Medical, Scientific and AI Officer, Cleerly * Neerav Sheth, MD, MBA, Interventional Cardiologist, Cardiology Consultants of Philadelphia * Brittany Weber, MD, PhD, Director, Cardio-Rheumatology/Cardio-Dermatology Program, UT Southwestern * 9:30-10:15 AM | Poster Session 2, #417: Beyond Risk Factors: Additive Role of Noncalcified Plaque Volume in Risk Stratification for Cardiovascular Events * 9:30-10:15 AM | Poster Session 13, #526: Age- and Sex-Specific Plaque Percentiles and Absolute Risk Zones from AI-QCT: Insights from CONFIRM2 * 2:55-3:15 PM | Product Showcase: Turning Insights into Action: The Purpose-Built Evolution of Cleerly | Product Showcase Theater * 3:30-5:00 PM | AI Plaque Wars! Chula Vista 6 * 5:34-5:42 PM | Novel Technologies: Why the Next Five Years will be Transformational: New Programs, New Science | Chula Vista 4 Saturday, July 11 * 10:55-11:40 AM | Poster Session 20, #599: Impact of Statin and Aspirin on Plaque Composition: Data from the CONFIRM2 Registry * 10:55-11:40 AM | Poster Session 20, #601: Association of Cardiac Symptoms with Quantitative Coronary Atherosclerosis, Stenosis, and Ischemia: Results from the CONFIRM2 Registry * 10:55-11:40 AM | Poster Session 20, #612: AI-Derived Plaque Quantification and Risk Stratification in Asymptomatic Individuals: A Sub-analysis of the CONFIRM2 Registry * 10:55-11:40 AM | Poster Session 20, #628: Discordance between PREVENT Clinical Risk Score, Coronary Artery Calcium, and Quantitative Non-Calcified Plaque in Asymptomatic South Asian Adults: Insights from the SACTA Registry * 1:40-2:10 PM | Meet and Greet with Cleerly Leadership | Booth #301 Cleerly at SCCT2026 Join Cleerly on Friday, July 10, from 7:00-7:50 AM for Cleerly's Breakfast Symposium at Chula Vista 6 and Saturday, July 11, from 1:40-2:10 PM at Booth #301 for a meet-and-greet with Cleerly's leadership team. Stop by Booth #301 throughout the conference for live demonstrations of Cleerly's technology, clinical evidence, and discussions with its expert team. A barista will be on-site Friday and Saturday throughout exhibit hall hours. To view the full schedule of Cleerly presentations or to schedule a meeting with Cleerly leadership, visit cleerlyhealth.com/scct-2026. About Cleerly Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.

PR Newswire
May 20th, 2026
MemorialCare becomes first LA County hospital to offer Cleerly AI heart disease analysis

MemorialCare has implemented Cleerly, an FDA-cleared AI-powered coronary analysis technology, across its hospital system, making Long Beach Medical Center the first hospital in Los Angeles County to offer the service. The technology is also available at Orange Coast Medical Center and Saddleback Medical Center. Cleerly enhances standard coronary CT angiography by identifying and measuring both calcified and non-calcified plaque in coronary arteries. The AI system specifically detects soft plaque, which is more likely to rupture and cause heart attacks but often missed by traditional imaging methods. The noninvasive technology is covered by Medicare and major commercial insurers including UnitedHealthcare, Aetna, Cigna and Humana for symptomatic patients. Results are reviewed by board-certified physicians and discussed during individualised consultations with patients.